These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 36093721)
1. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor. Jing X; Zhu H; Li Y; Jia W; Zhai X; Li J; Yu J Immunotherapy; 2022 Oct; 14(14):1097-1107. PubMed ID: 36093721 [TBL] [Abstract][Full Text] [Related]
2. Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. Tateo V; Manuzzi L; De Giglio A; Parisi C; Lamberti G; Campana D; Pantaleo MA Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260538 [TBL] [Abstract][Full Text] [Related]
3. Understanding the landscape of immunotherapy in thymic epithelial tumors. Maniar R; Loehrer PJ Cancer; 2023 Apr; 129(8):1162-1172. PubMed ID: 36808725 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. Ao YQ; Gao J; Wang S; Jiang JH; Deng J; Wang HK; Xu B; Ding JY Mol Cancer; 2023 Apr; 22(1):70. PubMed ID: 37055838 [TBL] [Abstract][Full Text] [Related]
5. Thymic epithelial tumor medical treatment: A narrative review. Huang Q; Zhu L; Liu Y; Zhang Y Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189167. PubMed ID: 39117091 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for thymoma. Jakopovic M; Bitar L; Seiwerth F; Marusic A; Krpina K; Samarzija M J Thorac Dis; 2020 Dec; 12(12):7635-7641. PubMed ID: 33447455 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors. Lucà S; Accardo M; Campione S; Franco R Explor Target Antitumor Ther; 2024; 5(3):465-476. PubMed ID: 38966177 [TBL] [Abstract][Full Text] [Related]
8. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy. Yang Y; Yu Y; Fan Y; Li H Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189145. PubMed ID: 38942215 [TBL] [Abstract][Full Text] [Related]
10. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review. Song X; Fan J; Zhu L; Wang Z; He Y; Zhou C J Thorac Dis; 2021 Aug; 13(8):5093-5103. PubMed ID: 34527346 [TBL] [Abstract][Full Text] [Related]
12. Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors. Mullenix C; Ballman M; Chen H; Swift S; McAdams MJ; Tsai YT; Donahue RN; Poretta T; Gupta S; Loehrer PJ; Schlom J; Gulley JL; Rajan A Oncologist; 2022 Apr; 27(4):e353-e356. PubMed ID: 35380721 [TBL] [Abstract][Full Text] [Related]
13. Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report. Shen L; Chen H; Wei Q Front Immunol; 2021; 12():621858. PubMed ID: 33936037 [TBL] [Abstract][Full Text] [Related]
14. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Conforti F; Zucali PA; Pala L; Catania C; Bagnardi V; Sala I; Della Vigna P; Perrino M; Zagami P; Corti C; Stucchi S; Barberis M; Guerini-Rocco E; Di Venosa B; De Vincenzo F; Cordua N; Santoro A; Giaccone G; De Pas TM Lancet Oncol; 2022 Oct; 23(10):1287-1296. PubMed ID: 36096156 [TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis. Remon J; Villacampa G; Facchinetti F; Di Maio M; Marcuse F; Tiseo M; Hochstenbag M; Hendriks LEL; Besse B Eur J Cancer; 2023 Feb; 180():117-124. PubMed ID: 36592506 [TBL] [Abstract][Full Text] [Related]
17. Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report. Liu S; Ma G; Wang H; Yu G; Chen J; Song W Medicine (Baltimore); 2022 Nov; 101(46):e31873. PubMed ID: 36401466 [TBL] [Abstract][Full Text] [Related]
18. Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses. Ishihara S; Okada S; Ogi H; Kodama Y; Shimomura M; Tsunezuka H; Itoh K; Marx A; Inoue M Lung Cancer; 2020 Jul; 145():40-47. PubMed ID: 32402921 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword. Ballman M; Zhao C; McAdams MJ; Rajan A Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565190 [TBL] [Abstract][Full Text] [Related]
20. Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review. Konstantina T; Konstantinos R; Anastasios K; Anastasia M; Eleni L; Ioannis S; Sofia A; Dimitris M Lung Cancer; 2019 Sep; 135():29-32. PubMed ID: 31446999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]